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Background: To establish a generalized equivalent uniform dose (gEUD) -based prescription method for Image
Guided Brachytherapy (IGBT) that reproduces the Gyn GEC-ESTRO WG (GGE) prescription for cervix carcinoma
patients on CT images with limited soft tissue resolution.
Methods: The equivalence of two IGBT planning approaches was investigated in 20 patients who received external
beam radiotherapy (EBT) and 5 concomitant high dose rate IGBT treatments. The GGE planning strategy based on
dose to the most exposed 2 cm3 (D2cc) was used to derive criteria for the gEUD-based planning of the bladder
and rectum. The safety of gEUD constraints in terms of GGE criteria was tested by maximizing dose to the gEUD
constraints for individual fractions.
Results: The gEUD constraints of 3.55 Gy for the rectum and 5.19 Gy for the bladder were derived. Rectum and
bladder gEUD-maximized plans resulted in D2cc averages very similar to the initial GGE criteria. Average D2ccs and
EUDs from the full treatment course were comparable for the two techniques within both sets of normal tissue
constraints. The same was found for the tumor doses.
Conclusions: The derived gEUD criteria for normal organs result in GGE-equivalent IGBT treatment plans. The
gEUD-based planning considers the entire dose distribution of organs in contrast to a single
dose-volume-histogram point.
Keywords: Image guided brachytherapy, Planning study, Equivalent uniform dose, Dose volume constraints,
Comprehensive volume, Worst case estimateBackground
Recently, the treatment of cervical cancer has been ad-
vanced through the use of image guided brachytherapy
(IGBT) [1-4]. The Groupe Européen de Curiethérapie
(GEC) and the European SocieTy for Radiotherapy &
Oncology (ESTRO) working group (Gyn GEC-ESTRO
WG, GGE) presented guidelines that comprise imaging
and organ segmentation for planning of every treatment
fraction [5,6]; subsequently, limited imaging approaches
have been derived [7,8]. Such an approach adapts for
organ motion and tumor shape changes by conforming
the prescribed dose to the target volume of the day, and* Correspondence: shaww@ufs.ac.za
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stated.thereby increases the chance of applying effective IGBT
doses in successive fractions. This image- and volume-
based planning strategy allows for a per-fraction analysis
of dose distributions and dose volume histograms (DVHs).
Further, the total delivered dose up to and including the
last treatment fraction can be estimated for clinical target
volumes (CTV) and organs at risk (OAR). This constitutes
a risk-controlled dose prescription method with DVH cri-
teria for tumor and normal tissue volumes. The relevance
of these criteria has been demonstrated by linking them to
toxicity [9-11] and local control [11-14]. However, con-
touring and organ motion are the major contributors of
uncertainties in IGBT [15].
The GGE technique requires MRI for tumor and OAR
delineation with applicators in-situ. Unfortunately many
clinics have limited availability of MRI. One alternativetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Patient, volume and treatment characteristics
Characteristic No of patients and/or value(s)
Total nr of patients 20
Total EBT dose 50 Gy
Total nr of EBT fractions 25
Total nr of IGBT fractions 5
Total IGBT dose (Mean ± SD) 4.7 ± 0.8 Gy





Volume in cc (Mean ± SD)
HR-CTV @ 1st IGBT treatment 49.0 ± 21.0
IR-CTV @ 1st IGBT treatment 119.0 ± 43.0
Rectum 94.8 ± 32.6
Bladder 108.0 ± 91.6
Dose objectives/constraints
HR-CTV D90 ≥ 85 Gy
IR-CTV D90 ≥ 60 Gy
Rectum D2cc ≤ 70 Gy
Bladder D2cc ≤ 80 Gy
Abbreviations: SD standard deviation, cc cubic centimeters.
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planning results in increased OAR volumes, CTV delin-
eation uncertainty and consequently unnecessarily large
CTVs, as one tends to plan conservatively [16-19]. These
uncertainties can produce lower CTV doses [3,16] if
normal tissue DVH criteria are adhered to. At the same
time, contour uncertainty leads to uncertainty of derived
DVH criteria for toxicity scoring or tumor control and
an uncertainty in the addition of OAR and tumor DVHs
for obtaining worst-case estimates of the accumulated
dose [6,15,20,21]. Furthermore, with the increased use of
more conformal external beam radiotherapy (EBT) tech-
niques such as intensity modulated radiotherapy (IMRT),
the addition of DVH parameters for such worst case esti-
mates can become unreliable.
This raises the question whether a volume-based treat-
ment plan metric such as the equivalent uniform dose
(EUD) [22] could be more robust against contouring and
imaging uncertainties than DVH. In EBT planning, the gen-
eralized EUD (gEUD) is well established [23-25] and is
mathematically equivalent to the DVH reduction scheme of
the Lyman-Kutcher-Burman (LKB) normal tissue compli-
cation probability (NTCP) model [26-29]. It is our intention
to establish a gEUD-based prescription method for IGBT
that can replace the original GGE prescription in terms of
dose-volume criteria, but offers advantages in terms of
safety and robustness against uncertainties. Further, EUD
sports favorable mathematical properties that allow a reli-
able worst-case estimate of the accumulated dose.
We investigate this question with a three-stage planning
study of fractionated IGBT. In stage 1, we record the EUD
values of OARs achieved with plans obtained from the
dose-volume constrained GGE guidelines. From this, we es-
tablish corresponding EUD criteria. In stage 2, the treat-
ments are planned according to these EUD constraints, and
their safety is assessed according to the GGE DVH criteria.
Finally, in stage 3, the full treatments (EBT + 5 fractions
IGBT) of both strategies are compared by both metrics.
Methods
Patient selection, imaging and contouring
Ethical approval (ETOVS NR 214/09) was received for
this study. Twenty patients who had been treated with
high dose rate (HDR) IGBT for carcinoma of the cervix
between October 2009 and January 2011 were randomly
selected (Table 1). All patients received EBT consisting
of 25 fractions of 2 Gy via a 4-field box technique without
midline shielding, and 5 concomitant IGBT treatment frac-
tions of 4.7 Gy (± 0.8 Gy) to the High Risk CTV (HR-CTV;
discussed below) with a standard magnetic resonance im-
aging compatible tandem-ring (Nucletron®). Intra-uterine
source positions were located at 1 cm intervals from the
ring to the tip, while the length of the intra-uterine applica-
tor was adapted to tumor extent. Source positions in thering were fixed for all treatments. Our center’s high work-
load requires that implantations be done under conscious
sedation without vaginal packing. Treatment plans were
produced on axial CT images for lack of MRI facilities.
Contouring was based on clinical examination and CT
images, using the GGE guidelines for the HR-CTV, Inter-
mediate Risk CTV (IR-CTV) and the rectum and bladder
walls. The GTV had to be omitted as it cannot be identi-
fied on CT images. The HR-CTV consisted of the whole
cervix and macroscopic extent of the disease at the time
of imaging for IGBT. The IR-CTV encompassed the HR-
CTV plus a variable margin depending on the initial extent
of the disease, considering tumor regression in response to
treatment. The OAR walls and outline with content were
delineated according to the same set of recommendations.
Fractionation and dose evaluation parameters
According to the GGE recommendations we recorded the
following parameters for purposes of comparison: Min-
imal dose received in 0.1, 1, and 2 cc of the maximal dose
regions of the OARs (D0.1, 1, 2 cc; outer wall plus con-
tent), dose to 90% (D90) of the HR- and IR-CTVs, as well
as the EUDs of OAR walls and CTVs.
Full DVHs of each treatment fraction were available
in the Flexiplan (Nucletron®) treatment planning system
and dose was converted to a 2 Gy equivalent dose (EQD2)
[30]. According to GGE, the linear quadratic (LQ) model
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mors (α being 0.3 Gy-1) were applied. Since the treatment
was concomitant HDR brachytherapy, repair half-times
and repopulation were neglected.
The EUD for target volumes was calculated relative to
the EBT dose delivered in 2 Gy fractions (d = 2 Gy) from
the surviving fraction as:
EUD ¼ −Log Sð Þ
αþ βd ð1Þ
To consider the heterogeneity in dose distributions,
the differential DVH of tumors was used to calculate the
surviving fraction for each treatment:
S ¼ ΣkvkS Dkð Þ ð2Þ
S is calculated from Dk, the dose bin for the vk−th frac-
tional tumor volume.
The gEUD calculation was used for OARs [28,31],
again considering a reference dose of 2 Gy per fraction
and is given by
gEUD ¼ ΣkvkDkað Þ1a ð3Þ
where Dk is the EQD2 for the vk−th fractional OAR vol-
ume and a is the volume effect parameter. The gEUD
for rectum and bladder walls was calculated using vol-
ume effect parameters (a) of 12 for the rectum and 8 for
the bladder [23,32,33].
For simplicity we refer to the EUD based, adaptive IGBT
planning strategy as the comprehensive volume technique
(CV), emphasizing the fact that EUD considers the entire
organ volume.
Study 1: prescription constraints
One possibility to establish the gEUD prescription con-
straints for IGBT treatment planning is to collect them
from literature, another by a planning study. From Söhn
et al. (2007), we can choose the gEUD upper limit for
the rectum to be 67.8 Gy (3.55 Gy EUD per IGBT frac-
tion), at approximately 10% NTCP for grade II (G2) rectal
bleeding. However, in the following this gEUD is verified
against a rectum D2cc constraint of 70 Gy EQD2 [9,10] by
the planning study. Bladder NTCP model data are scarce
and uncertain [34] due to unaccounted variations in filling.
Consequently, the bladder gEUD constraint is determined
by the planning study. There are bladder dose guidelines
based on the GGE work that show more than 5 - 10% late
complication rates when the D2cc is in the order of 70–
100 Gy EQD2 [9,10,19,35,36].
To derive the bladder wall gEUD dose constraints, the
GGE planning strategy was followed to achieve at least
7.0 Gy per fraction (85 Gy EQD2 from EBT and IGBT)
to the HR-CTV D90. Treatment plans were produced for
each treatment fraction on the 100 CT datasets. Each planstarted from the standard loading pattern and was manually
or graphically optimized until the HR-CTV dose objective
was reached, or until one of the two OAR constraints
in question prevented any further CTV dose escalation
(Table 1). Bladder EUD constraints: HR-CTV dose was
further increased beyond the CTV objective until the
bladder D2cc criterion was reached. This constraint was
chosen as 80 Gy total dose from EBT and IGBT, resulting
in 6 Gy EQD2 per IGBT fraction. The procedure was re-
peated on all plans and for each the associated bladder
wall gEUD was computed. Consequently, the bladder
wall gEUD is solely determined by the D2cc of the blad-
der and is not influenced by any other OAR criterion or
the CTV doses. Rectum EUD constraints: To verify the
chosen gEUD of 67.8 Gy for an upper rectal limit, we re-
peated this constraint derivation procedure for the rectal
wall by limiting the total rectum D2cc EQD2 to 70 Gy
(4.0 Gy EQD2 per fraction).
All 100 “bladder-limited” plans are maximized to the
bladder constraint of 6.0 Gy D2cc per fraction and the
corresponding bladder wall gEUDs were recorded and
all 100 “rectum-limited” plans are maximized to the rec-
tum dose constraint of 4.0 Gy D2cc and the associated
rectum wall gEUDs were recorded. From these data, the
variation in bladder and rectal wall gEUD at fixed DVH
criteria could be found and the EUD criteria could be de-
rived or verified from these gEUD frequency distributions.
Study 2: safety of EUD constraints in terms of
GGE constraints
To test the safety of the CV technique, we investigated the
appropriateness of the bladder- and rectum wall EUD
constraints in terms of the GGE dose volume criteria.
Here we maximized the same dose distribution as in study
1 for each treatment plan, but to the point where the blad-
der wall gEUD constraint was reached instead of the D2cc
constraint. At this point we recorded the corresponding
D2cc (and other DVH parameters). This procedure was
repeated for the rectal wall by maximizing dose to the rec-
tum gEUD constraint. Thus a single plan was optimized
against each of the organs at risk separately.
Study 3: comparison of GGE and CV planning strategies
for the entire treatment
Once the robustness of the CV technique in each fraction
has been established, the two planning strategies can be
compared in terms of OAR and CTV dose for a full treat-
ment. The GGE based plans for each patient and each frac-
tion adhered to the two OAR D2cc constraints (Table 1)
per fraction, whichever was met first. The HR-CTV D90
was targeted to be at least 85 Gy in total. No upper CTV
constraints were set and dose was maximized until an
OAR D2cc constraint was reached. The total dose from
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Figure 1 GGE planning strategy: Bladder and rectal wall EUD frequency distributions. Frequency distributions of bladder (a) and rectum
(b) wall EUDs when dose is maximized to 6 Gy D2cc for bladder and 4 Gy D2cc for rectum.
Table 2 Summary of the statistical parameters of the
gEUD variations with D2cc and EUD criteria
























Abbreviations: SD standard deviation.
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earlier. Finally, the two strategies could be compared in
terms of D90, D2cc and EUD.
Results
Prescription constraints
The frequency distributions of the OAR wall EUDs for
bladder-limited and rectum-limited plans are displayed
in Figure 1. Table 2 provides a summary of the statistics.
The spread of EUDs results from the fact that the gEUD
is calculated from the full OAR DVH while D2cc is lim-
ited to a small volume. Furthermore, the D2cc volume
may often include organ contents. Notice further some
extreme outliers, which are a consequence of an unfavor-
able organ location in some fractions that brings large
parts of the organ close to the high dose range, but below
the D2cc criterion.
The average gEUD of the rectal wall at a D2cc con-
straint of 4.0 Gy was 3.67 Gy (±0.53 Gy) which is compar-
able to the 3.55 Gy from our external beam rectum EUD
constraint choice. If this average gEUD was reached in all
of the 5 fractions, the NTCP would be ranking at approxi-
mately 11%. The average bladder gEUD at a D2cc con-
straint of 6.0 Gy was 5.19 Gy (±1.25 Gy). The values:
rectum wall gEUD ≤ 3.55 Gy and bladder wall gEUD ≤
5.19 Gy were established as the upper limits for the CV
technique. Thus, the total EUD constraint for the bladder
wall equals 75.95 Gy.
Safety of EUD criteria in terms of GGE criteria
The safety of these EUD criteria was verified by compar-
ing the D2cc values of CV plans with those obtained from
the GGE strategy. Figure 2 shows the distribution of D2cc
for the OARs with the EUD criteria as determined in the
previous section, while Table 2 compares the D2cc statis-
tics of the frequency distributions. Figure 2 shows that the
D2cc distributions are skewed towards lower values and
show no outliers towards high doses. The mean of the
D2cc distributions closely resembles the GGE criteria, see
Table 2. For a fractionated treatment, the EUD criteria can
thus be considered safe, because even in the worst case(the same organ is dose-limiting in all fractions) the sum
of the D2cc of n fractions is likely to be smaller or equal
to n times the mean D2cc of the distributions, due to their
left-skew. Since the choice of EUD criteria is somewhat ar-
bitrary, we identified those levels, gEUD(x), that result in
no more than x% of the 100 treatment plans exceeding
the associated GGE criterion, see Table 3.
We have also found very good correlations between
D0.1 cc and D2cc for the rectum (R2 = 0.84), as well as ex-
cellent correlation between D1cc and D2cc for the rectum
(R2 = 0.96). This means that if D2cc can be controlled via




























CV planning strategy: Rectum D2cc
Frequency Distribution
b
Figure 2 CV planning strategy: Bladder and rectal D2cc frequency distributions. Frequency distributions of the bladder (a) and rectum
(b) D2ccs when expanding the dose distribution to 5.19 Gy EUD for bladder and 3.55 Gy EUD for rectum.
Shaw et al. Radiation Oncology 2013, 8:266 Page 5 of 10
http://www.ro-journal.com/content/8/1/266bleeding will also be controlled. Similarly, we have found
excellent correlation between bladder D1cc and D5cc with
D2cc (R2 = 0.95 and R2 = 0.93 respectively), and a worse
correlation between D0.1 cc and D2cc (R2 = 0.63).
Comparison of GGE and CV planning strategies
The two planning approaches were compared in terms of
total dose from all 5 IGBT fractions plus the EBT compo-
nent for the patients in the study. Very similar total dose
parameters for the two techniques were found. Figure 3 dis-
plays the total dose in the two planning techniques for rec-
tum and bladder D2cc, and HR- and IR-CTV D90. Figure 4
displays the rectal and bladder wall gEUDs, and the HR-
and IR-CTV EUDs. Table 4 provides the average and stand-
ard deviations of their frequency distributions, indicating
very similar means.
Discussion
We have established OAR gEUD criteria for IGBT treat-
ments that are very comparable to those obtained from
the GEC-ESTRO guidelines. EUD constraints can thus be
considered a safe and efficient alternative to D2cc criteria.
Compared to a D2cc constraint, which considers an
isolated small volume, gEUD has the advantage to con-
sider the dose distribution in the OAR comprehensively
and still give high doses a large weight, especially if the
volume effect parameter a is significantly greater than 1.
For the same reason, it is also less sensitive to contour-
ing and may therefore be a more robust choice if MRI is
not available for IGBT planning. To see this, assume
that contouring errors lead to errors in the volume ofTable 3 Different gEUD(x) levels resulting in percentage x of
constraint and mean and standard deviations of the resulting
x % of treatment fractions Rectum gEUD(x) (Gy) Rectum mean D2c
10 3.12 3.49 ± 0.4
25 3.35 3.74 ± 0.4
48 3.55 3.96 ± 0.4
50 3.58 3.99 ± 0.5
70
Abbreviations: SD standard deviation.the dose bins of the DVH. Applying the laws of error
propagation, we find that the error in D2cc is propor-
tional to the inverse slope of the DVH at D2cc (which
tends to be shallow in BT) and proportional to the vol-
ume error at that dose bin. In contrast, the error in
gEUD is both proportional to the weighted root-mean-
square of the volume errors in the dose bins (thus less
dependent on a single bin) and smaller by a factor 1/a.
This ties in with the intuition, that any kind of average
over a number of uncertain quantities (such as EUD) is
less uncertain than any single one of these quantities.
The derived EUD criteria depend on the reference D2cc
criteria and the volume effect parameter a. Since gEUD
is a power-law function of dose, it scales with the same
factor as D2cc. Small deviations from this law are caused
by the EQD2 correction. Within reason, our criteria can
therefore be calibrated to different fractionation schemes,
i.e. scaled by the ratio of the desired D2cc versus the value
used here.
The volume effect parameters (a = 8 for bladder, a = 12
for rectum) are derived from the literature. They do ex-
press a very small volume effect of the complications in
question, which is also the implicit rationale behind the
D2cc criterion. We confirm that the influence of the
choice of a on our results is small, although safer when
a ≥ 8, since D2cc becomes increasingly smaller with a large
a at fixed constraint levels; see a value variance in Table 5.
It is thus considered safe to err towards large a values, i.e.
smaller volume effect, when the exact value is not known.
Occasionally, the use of EUD criteria for IGBT is safer
than D2cc. Observe the outliers in Figure 1 which aretreatment fractions with D2cc larger than the GGE
distributions
c ± SD (Gy) Bladder gEUD(x) (Gy) Bladder mean D2cc ± SD (Gy)
3 4.22 5.11 ± 0.81
6 4.48 5.42 ± 0.86
9
0 4.86 5.87 ± 0.94



























































Total IR-CTV D90 per patient
d
Figure 3 Total DVH parameters per patient. Total EQD2 for bladder (a) and rectum (b), and D90 for the HR- (c) and IR-CTV (d). Data are
shown for the GGE technique (circles) and the CV technique (diamonds).
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a lot of the organ volume close to the high dose region.
In contrast, EUD criteria do not produce excessive D2cc
values because of their mathematical construction, which
gives very high weights to sub-volumes with a high dose.
From Table 2, the average D2cc for the OARs, when dose
is maximized to each OAR’s gEUD constraint, is virtually
the same as the GGE-D2cc that was used to derive the
EUD criteria. Although there is some dispersion of D2ccs
around this average, none of the D2ccs were found to be






























Total HR-CTV EUD per patientc
Figure 4 Total EUD per patient. Total EUD for bladder (a) and rectal wal
(circles) and the CV technique (diamonds).shown in Table 3, to decrease D2cc constraint violations,
small changes in EUD result in large reductions in D2cc
and a smaller variance of D2cc. Our results suggests that
a 6 to 8% reduction in OAR gEUDs produce more than
25% fewer treatment plans that could violate a D2cc con-
straint. Since we know that D0.1 cc and D1cc also corre-
lates well with D2cc, CV plans that control D2cc would
subsequently control the resultant D0.1 cc and D1cc DVH
parameters as well.
The D2ccs of the CV technique are evaluated against






























Total IR-CTV EUD per patientd
l (b), HR- (c) and IR-CTV (d). Data are shown for the GGE technique
Table 4 Summary of the statistical variations of the DVH
parameters and EUD variations over the full
treatment course
Statistical measure Technique Rectum Bladder HR-CTV IR-CTV
D2cc D2cc D90 D90
Mean (Gy) GGE 64.85 78.29 108.49 75.85
SD 3.10 2.29 20.59 5.22
Mean (Gy) CV 64.51 77.87 107.77 75.36
SD 3.20 3.70 21.95 6.16
gEUD gEUD EUD EUD
Mean (Gy) GGE 63.66 74.53 114.28 81.51
SD 3.42 4.58 16.40 4.12
Mean (Gy) CV 63.18 73.32 113.58 81.19
SD 3.07 3.31 17.90 5.07
All values in Gy.
Abbreviations: SD standard deviation.
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mizing OAR dose to the EUD constraints does not result
in OAR over-dosage. The total average bladder and rec-
tal D0.1, D1 and D2cc when OAR dose is maximized to
the EUD constraints falls in a lower range than those
presented by Georg et al. for LENT/SOMA scores of 1–4
and VRS scores of 3–5 [9]. The population averages in
their studies [9,10] are comparable to the dose levels in
this study. We have also found that especially the rectal
doses in this study are in the lower range of toxicity rates
for G2-4 side effects. Based on the Georg et al. studies
[9,10,35], our criteria relate to a probability of finding G2-
G4 side effects in the range of 5-10%.
These dose endpoints are also very comparable with
studies where large HR-CTV volumes were investigated
and no interstitial needles were used. As shown in the
study of Jürgenliemk-Schulz et al. [36], we expect that
interstitial needles would decrease the EUD of OARs in
large tumor volume cases as well. For bladder, we foundTable 5 Variation of gEUD and D2cc for different values of th
Volume parameter (a) Rectum gEUD constraint (Gy)* Rectum D2
8 3.09 ± 0.37 4.66 ±
9 3.26 ± 0.42 4.43 ±
10 3.41 ± 0.46 4.24 ±
11 3.54 ± 0.50 4.09 ±
12 3.67 ± 0.53 3.96 ±
13 3.78 ± 0.56 3.85 ±
14 3.88 ± 0.59 3.75 ±
15 3.97 ± 0.61 3.67 ±
16 4.06 ± 0.63 3.60 ±
*Calculated with a 4.0 Gy rectum D2cc constraint.
**Calculated with a 6.0 Gy bladder D2cc constraint.
#Calculated with a 3.55 Gy (a = 12) rectum gEUD constraint.
##Calculated with a 5.19 Gy (a = 8) bladder gEUD constraint.good correspondence with the results of Levitchi et al.
[37], Jürgenliemk-Schulz et al. [36,38], Nesvacil et al.
[39] and Lindegaard et al. [40]. Since there were no
upper dose boundaries for the CTV, the CTV dose is ex-
pected to spread widely, driven solely by the OAR geom-
etries and relative positions. From Figures 3 and 4 it is
clear that the CV technique does not result in under-
dosage of the CTVs.
An important aspect of gEUD is, that it allows an easy
worst-case estimate of the gEUD of the total accumu-
lated treatment dose by virtue of Jensen’s inequality
[41,42]. The sum of EUDs of each treatment fraction is
always greater or equal (for OARs; smaller or equal for
targets) to the EUD of the sum of the fraction doses:
EUDðE½D̃Þ≤E½EUDðD̃Þ ¼ E EUD Dð Þ½  ð4Þ
where E[] is the sum over all fractions, D ̃ is the dose of
each fraction, warped to reference geometry, and D the
dose as computed for the patient geometry of the particu-
lar fraction. Hence, the left hand side is the EUD of the
properly accumulated total dose, while the right hand side
is the sum of the EUDs as computed for each fraction in-
dividually. For target volumes, the inequality reverses. This
estimate is of particular importance for pelvic radiother-
apy, where deformable registration of images is difficult to
perform reliably. Hence, EUD addition gives a worst case
scenario for OARs and CTV without the need for deform-
able image registration and dose warping [42].
D2cc is not a convex function of dose and is not addi-
tive in a strict sense, so that further assumptions about
the dose distribution have to be made. Jensen’s inequal-
ity also applies to maximum and minimum dose, so that,
if D2cc and D90 have a strong correlation to the former,
the inequality holds for the latter approximately “by proxy”.
The versatility of EUD summation as worst case estimatee gEUD volume parameter
cc (Gy)# Bladder gEUD constraint (Gy)** Bladder D2cc (Gy) ##
0.52 5.19 ± 1.25 6.25 ± 1.01
0.51 5.56 ± 1.44 5.89 ± 1.00
0.50 5.89 ± 1.61 5.60 ± 0.99
0.50 6.19 ± 1.77 5.35 ± 0.97
0.49 6.46 ± 1.91 5.15 ± 0.96
0.49 6.72 ± 2.04 4.98 ± 0.95
0.48 6.95 ± 2.16 4.83 ± 0.93
0.48 7.17 ± 2.26 4.70 ± 0.92
0.47 7.36 ± 2.36 4.59 ± 0.91
Table 6 Summary of the average DVH parameters in total dose (Gy) of the CV treatment technique, compared to other published values




Nesvacil et al. [40] Lindegaard
et al. [41]
Method HDR HDR HDR PDR PDR HDR/PDR HDR PDR
Rectum
D0.1 cc 79 ± 1 88 ± 10* 83 - 132 a 83 b
81 ± 13** 86 ± 27** 65 ± 15** 74 ± 9**
D1cc 72 ± 2 76 ± 7* 71 - 87 a
70 ± 9** 69 ± 14** 69 ± 6**
D2cc 70 ± 2 72 ± 6* 67 - 78 a 68 b
66 ± 8** 65 ± 12** 57 ± 8** 66 ± 6** 54 ± 2**c 57 ± 6** 67 ± 6**
69 ± 2** d
Bladder
D0.1 cc 100 ± 3 61 - 178 a 109 b
162 ± 75** 78 ± 22** 86 ± 12**
D1cc 86 ± 3 71 - 116 a
108 ± 31** 77 ± 8**
D2cc 81 ± 3 70 – 101a 72 b 81 ± 6** 53 ± 2** c 76 ± 9**
95 ± 22** 64 ± 11** 101 ± 11** d 73 ± 6**
Abbreviations: SD standard deviation, HDR high dose rate, PDR pulsed dose rate.
*Clinical symptoms (LENT/SOMA) score 1–4 and Rectoscopic changes (VRS) score 3–5.
**Population average; no interstitial needles.
a5% - 10% probability of G2-G4 side effects (dose range not shown).
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doses, for example lymph node boosts. Finally, because
there is a variability in reported dose-volume cut-offs for
OARs in IGBT [9,35,37,43] and these also differ from cut-
offs in EBT, EUD is helpful in combining the experience in
both areas and relating it to the LKB model [44]. Con-
versely, documented brachytherapy toxicity rates can be
useful for focused dose escalation in EBT, for example dose
painting.
Conclusions
Concluding, a GEC-ESTRO-like IGBT plan adaption is
feasible with EUD criteria, instead of D2cc criteria. Be-
cause of the mathematical construction of gEUD, and the
fact that it considers the organ volume comprehensively,
it is inherently more robust against contouring uncertain-
ties. This could make gEUD a better choice than D2cc if
IGBT has to be performed on CT, instead of MR, images.
The summation of EUDs per treatment fraction gives a
reliable worst case estimate of the total treatment dose,
which opens possibilities for safe dose escalation in IGBT
or simultaneous integrated boost in EBT.
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